| AbbVie AG - Rinvoq 15 mg, Retardtabletten | | 67257 | | 01 | | Rinvoq 15 mg | | Retardtabletten | | L04AF03 | | | | 20.01.2020 | | |
| | Composition | | upadacitinibum 15 mg ut upadacitinibum hemihydricum, cellulosum microcristallinum, hypromellosum, mannitolum, acidum tartaricum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, E 171, E 172 (nigrum), E 172 (rubrum), pro compresso obducto. | | Packungsbestandteile | | Comprimés retards | | | | | Principe actif | Concentr. |
|---|
| Upadacitinibum | 15 mg |
| | BAG: Principe actif | Concentr. |
|---|
| Upadacitinibum | 15 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| (Nigrum) | | | | (Rubrum) | | | | Acide Tartarique | | | | Cellulosum Microcristallinum | | | | E 171 | | color. | | E 172 | | color. | | Hypromellosum | | | | Macrogol | 3350 | | | Magnesii Stearas | | | | Mannitol | | | | Poly(Alcohol Vinylicus) | | Überzug | | Pro Compresso Obducto | | | | Silica Colloidalis Anhydrica | | | | Talcum | | |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 001 | 28 | 765.24 | 848.65 | B | LS | Oui |
|
|
